GLOBAL DEAL SYNDICATION
HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.
UPCOMING SYNDICATION CALLS
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
OSTEOBOOST
Thursday, April 10, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter:
CEO & President, Laura Yecies, MBA'88
​
For HBS Angels Members ONLY
On behalf of the New York chapter, we would like to share the following investment opportunity:
​
Osteoboost is a precision vibration therapy medical device, clinically-proven to slow the loss of bone density and strength in postmenopausal women with osteopenia. Osteoboost is the first FDA-cleared prescription non-drug treatment for low bone density.
Company Overview:
At Osteoboost Health, we develop breakthrough solutions to help people defend against osteoporosis and osteopenia. Our mission is simple: to empower people to lead longer, stronger, and more active lives by safeguarding bone density from the effects of menopause, aging, cancer, and other degenerative causes of bone loss.
Our flagship product, Osteoboost, is a new way of thinking about an age-old problem: low bone density. It’s a prescription medical device, worn around the hips, that delivers clinically-proven targeted vibration therapy directly to the areas of the body most at risk of life-altering osteoporotic fractures. Osteoboost includes a comprehensive digital solution, including the recently acquired Wellen osteoporosis exercise program.
Osteoboost is an FDA-cleared treatment indicated for postmenopausal women with osteopenia. It fills a critical vacuum in the low bone density treatment and prevention space, and is drug-free, pain-free, and convenient for patients to use in their daily life.
​
Efficacy:
In a gold-standard double-blinded sham-controlled clinical trial at the University of Nebraska Medical Center, Osteoboost reduced the loss of bone strength in the vertebral spine by 83%, reduced the loss of bone density in the spine by 85%, and reduced the loss of bone density in the hips by 55%. The FDA cleared Osteoboost as a Class II Breakthrough Device through the De Novo pathway in 2024.
Sales Highlights To Date:
In November of 2024, we opened pre-orders to our waiting list, selling >1000 devices for over $1M in collected revenue. Over 950 unique medical providers have prescribed Osteoboost, some as many as 37 times (in 4 months) and physicians from more than 30 leading academic medical centers have prescribed. Osteoboost is expected to launch publicly in mid-April, 2025.
​
Financial and Business Projections:
$5M revenue 2025
$24M revenue 2026
$62M revenue, cash flow positive 2027.
Executive Team:
Our executive team offers deep business, scientific, and medical experience
-
CEO: Laura Yecies, MBA from Harvard, MSFS Georgetown
-
Chief Scientific Officer: Michael Jaasma, PhD in orthopedic biomechanics, UC Berkeley
-
Chief Medical Officer: Dr. Pamela Peeke, MD, MPH, FACP, FACSM, UC Berkeley, UC Davis
Raise :
$3.5M SAFE, 20% Discount, $35M Post Money CAP. We have raised $2.8M closed.
Laura Yecies
CO-FOUNDER & CEO, HBS MBA 1988
​Osteoboost CEO Laura Yecies is a healthtech leader and strategist with deep experience launching and scaling medical device and diagnostic companies. Prior to Osteoboost, she was CEO of NeuroSync, Catch (acq. by Apple), and SugarSync (acq J2Global). She holds an MBA from Harvard, MSFS from Georgetown, and AB from Dartmouth. Yecies is a highly-regarded speaker, podcaster, and writer on healthcare and technology.
PREVIOUS SYNDICATION CALL
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
SOTERI SKIN
Thursday, January 16, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenters:
Co-Founder & CMO, Lama Mansour, HBS MBA '06
Scientific Co-Founder & CEO, Dr. Rafal Pielak, HMS '11
​
For HBS Angels Members ONLY
On behalf of the Northern California chapter, we would like to share the following investment opportunity:
Developed at Harvard Biomedical Sciences & Harvard Innovation Lab, we are pleased to present Soteri Skin, the only non-steroidal, non-prescription, pH correcting and balancing eczema topical treatment that breaks the cycle of eczema and provides long-term relief from the debilitating effects of constant flare-ups, dryness, itchiness, irritation, and sleepless nights.
Company Overview: Soteri Skin Inc. is a medical skincare start-up that has participated in both the Y Combinator accelerator program (W22) and Harvard Innovation Labs.
At Soteri Skin, we are pioneering a new approach to treating Atopic Dermatitis (eczema) with our patented technology, the Soteri Skin pH/LOCK™ complex. This groundbreaking pathway works by repairing the skin barrier through an outside-in approach, restoring and maintaining optimal skin pH levels for up to 12 hours.
We are addressing a significant consumer pain point by breaking the cycle of eczema and providing long-term relief without steroids or continued biologic use.
Efficacy: Our clinical trials have yielded strong results, with 60% of patients achieving complete symptom relief within a 4-week period.
We are already approved by the FDA as an OTC medication.
Sales Highlights To Date: In February 2024, we launched our Direct-to-Consumer website and have already generated $120K in revenue, with minimal marketing efforts. To date, we've attracted 500 unique customers and are seeing an impressive 60% repeat purchase rate. We are also finalizing a licensing agreement for our pH/LOCK® technology with Essity, a global health and hygiene company.
Financial and Business Projections: With a $1.5MM seed round, we project:
-
$1.0M in revenue in Year 1
-
$15.7MM in Year 2 & break even
-
$216.7 M in revenue by 2030.
Founding Team:
Our founding team brings complementary skills:
-
CEO: Dr. Rafal Pielak, PhD, BioMedical Sciences, Harvard Medical School
-
Chief Marketing Officer: Lama Mansour, MBA, Harvard Business School
​
Raise : $1.5MM Seed Round on $9MM Post Money SAFE. We have raised $1.0MM to date.
Lama Mansour
CO-FOUNDER & CMO, HBS MBA 2006
Lama Mansour, Co-Founder and CMO of Soteri Skin with an MBA from Harvard Business School and over 20 years of expertise in brand management and marketing. Her diverse background spans the nutrition, skincare, and personal care sectors. Throughout her career, Lama has held leadership roles at global companies including General Mills International, Reckitt Benckiser, and Arbonne International. At Arbonne, she played a key role in launching the Nutrition category, and at Reckitt Benckiser, she successfully introduced the KY brand to the Canadian market. Lama is now passionately committed to establishing Soteri Skin as a leader in eczema relief and helping the millions affected by this condition.
Dr. Rafal Pielak
SCIENTIFIC CO-FOUNDER & CEO
Dr. Rafal Pielak, Scientific Co-Founder and CEO of Soteri Skin, earned his Ph.D. in Biomedical Sciences from Harvard Medical School and has over a decade of experience in product innovation and development in biotech and skin health. He was a founding member of the L'Oréal Tech Incubator in San Francisco, where he led a product innovation team, developing new products for La Roche-Posay, CeraVe, and SkinCeuticals. When his wife and daughter developed eczema, he made it his mission to find an effective solution to help them. This led him to extensive research and collaboration with leading dermatologists, resulting in the creation of Soteri Skin pH/LOCK technology, the only long term pH correcting skincare that provides long-term relief from eczema.
PAST SYNDICATED COMPANIES
 |  |  |
|---|---|---|
 |  |  |
 |  |  |
 |  |  |
 |  |  |
|  | |
 | |  |
 |  |  |
 |  |  |
 |  |  |
|  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |
HOW IT WORKS
Use arrows on the side to navigate
1. HOST CHAPTER
A company must meet a threshold of member investment in one of our HBS Alumni Angel Chapters listed here. The leadership of the host chapter nominates the company for global syndication and provides a local member contact to act as syndication lead and a company contact.
CRITERIA
Ideally, for global syndication a company should meet the following requirements:
-
Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication;
-
Company assures at least $50,000-100,000 investible capacity;
-
Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;
-
Minimum individual investment amount is set at $25,000 or less;
-
Company agrees to a one-time admin fee of $1500.
The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars.
​
*NY and other larger chapters may have a $100,000 min.